- Home
- TSVT
TSVT
2seventy bio Inc.
as 10-04-2024 3:36pm EST
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 253.9M | IPO Year: | N/A |
| Target Price: | $10.40 | AVG Volume (30 days): | 341.4K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.53 - $6.40 | Next Earning Date: | 11-12-2024 |
| Revenue: | $44,120,000 | Revenue Growth: | -70.04% |
| Revenue Growth (this year): | -36.26% | Revenue Growth (next year): | 22.42% |
Stock Insider Trading Activity of 2seventy bio Inc. (TSVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Snow Jessica | TSVT | See Remarks | Aug 14 '24 | Sell | $4.32 | 7,816 | $33,760.43 | 156,330 | |
| Eatwell Victoria | TSVT | Chief Financial Officer | Aug 5 '24 | Sell | $3.99 | 13 | $51.81 | 341,319 |
Latest 2seventy bio Inc. News
TSVT Breaking Stock News: Dive into TSVT Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
Business Wire
a month ago
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
Simply Wall St.
2 months ago
2seventy bio, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Business Wire
2 months ago
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
Business Wire
2 months ago
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
Simply Wall St.
3 months ago
Broker Revenue Forecasts For 2seventy bio, Inc. (NASDAQ:TSVT) Are Surging Higher
Business Wire
3 months ago
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
The Telegraph
4 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Compare TSVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TSVT 2seventy bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.